Why the study?
Do antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element inhibit Rev activity and HIV-1 replication in vitro?
Population
In vitro models (HeLa cells stably expressing HIV-1 Tat, Molt3 CD4+ cells infected with HIV-1 HTLV-IIIB)
Comparison
Antisense oligodeoxynucleotide phosphorothioate… vs Control S-ODNs or untreated cells
Design
Preclinical
Follow-up
Up to 63 days in persistent infection assay
Authors
Loading...
In vitro antiviral activity of Rev-targeted antisense ODNs is hypothesis-generating; does not support clinical translation without further validation.
Do antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element inhibit Rev activity and HIV-1 replication in vitro?
Antisense oligodeoxynucleotides targeting the HIV-1 Rev-responsive element specifically and persistently inhibit viral replication in vitro, suggesting potential as an antiviral therapy.
Li et al. (1993) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: